ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 894

Genetic Variants in the IL-4 and IL-4 Receptor Genes in Association with the Severity of Joint Damage in Rheumatoid Arthritis: A Study in Seven Cohorts

A. Krabben1, A. G. Wilson2, R. Knevel1, A. Zhernakova3, E. Brouwer3, E. Lindqvist4, T. Saxne4, G. Stoeken-Rijsbergen1, J. A. B. van Nies1, D. P. C. de Rooy1, T.W.J. Huizinga1, B. P. C. Koeleman5, R. E. M. Toes1, P. K. Gregersen6 and A. H. M. van der Helm-van Mil1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, 3Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands, 4Rheumatology, Lund University, Lund, Sweden, 5Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, 6Genomics and Human Genetics, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: genomics, interleukins (IL), joint destruction, meta-analysis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The severity of RA is reflected by the severity of radiological joint destruction. It is highly variable between patients and up to 58% of this variance is explained by genetic factors. In order to increase the understanding of the processes underlying joint damage progression, it is relevant to identify individual risk factors. In vitro studies and mice studies showed that IL-4 has a role in suppressing arthritis severity. The effect of IL-4 is mediated by a heterodimeric receptor composed of the IL-4R alpha chain. Several genetic variants in IL-4 and IL-4R have been described to associate with RA severity, though these findings have not been replicated. Together these data prompted us to investigate the association between IL-4 and IL-4R tagging SNPs and progression rate of joint damage in a multi-cohort candidate gene study.

Methods:

IL-4 and IL-4R tagging SNPs (8 and 39, respectively) were genotyped in 600 RA patients of whom 2,846 sets of hands and feet X-rays were collected during 7 years follow-up. Subsequently, significantly associated SNPs were genotyped and studied in relation to 3,523 X-rays of 2,064 RA patients of several European and North-American cohorts. These concerned data-sets from Lund (Sw) (781 X-rays in 147 patients), Sheffield (UK) (391 X-rays in 391 patients), Groningen (NL) (872 X-rays in 280 patients), NARAC (USA) (385 X-rays in 385 patients), Wichita (USA) (337 X-rays in 101 patients) and NDB (USA) (757 X-rays in 757 patients). Three SNPs of phase-2 were not available for the latter two cohorts. In all cohorts X-rays were scored with high reproducibility. The relative increase in progression rate per year in the presence of a genotype was determined, as this outcome measure is comparable between cohorts. Subsequently, since the individual replication cohorts had less number of X-rays than the discovery cohort, an inverse variance weighting meta-analysis was done on the cohorts that together formed the replication phase.

Results:

In the discovery phase none of the IL-4 SNPs and seven of the IL-4R SNPs were significantly associated with joint damage progression rate. In the replication phase, two SNPs in IL-4R gene were significantly associated with joint damage progression rate (rs1805011, p=0.017 and rs1119132, p=0.001). After Bonferroni correction for testing seven SNPs in phase-2 rs1119132 remained significantly associated with joint progression rate (pcorrected=0.007). Leiden RA-patients carrying both minor alleles of rs1119132 had a 1.09 fold rate of joint destruction compared to other patients, which corresponds to 81% higher rate of joint destruction over a period of 7 years.

Conclusion: rs1119132 in IL-4R was identified as well as independently replicated to associate with progression rate of joint damage in RA.


Disclosure:

A. Krabben,
None;

A. G. Wilson,
None;

R. Knevel,
None;

A. Zhernakova,
None;

E. Brouwer,
None;

E. Lindqvist,
None;

T. Saxne,
None;

G. Stoeken-Rijsbergen,
None;

J. A. B. van Nies,
None;

D. P. C. de Rooy,
None;

T. W. J. Huizinga,
None;

B. P. C. Koeleman,
None;

R. E. M. Toes,
None;

P. K. Gregersen,
None;

A. H. M. van der Helm-van Mil,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetic-variants-in-the-il-4-and-il-4-receptor-genes-in-association-with-the-severity-of-joint-damage-in-rheumatoid-arthritis-a-study-in-seven-cohorts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology